

Madan Jagasia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/362517/publications.pdf>

Version: 2024-02-01

100
papers

4,989
citations

172457

29
h-index

95266

68
g-index

100
all docs

100
docs citations

100
times ranked

5559
citing authors

#	ARTICLE	IF	CITATIONS
1	Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 98-102.	3.5	11
2	Longitudinal tracking of skin dynamic stiffness to quantify evolution of sclerosis in chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 989-991.	2.4	7
3	ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2021, 39, 1888-1898.	1.6	83
4	CMV exposure drives long-term CD57+ CD4 memory T-cell inflation following allogeneic stem cell transplant. <i>Blood</i> , 2021, 138, 2874-2885.	1.4	16
5	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	1.6	145
6	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 632-641.	1.2	21
7	Optimal Biomechanical Parameters for Measuring Sclerotic Chronic Graft-Versus-Host Disease. <i>JID Innovations</i> , 2021, 1, 100037.	2.4	5
8	Machine Learning Reveals Patient Phenotypes and Stratifies Outcomes in Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 2951-2951.	1.4	0
9	Early viral reactivation despite excellent immune reconstitution following haploidentical Bone marrow transplant with post-transplant cytoxan for sickle cell disease. <i>Transplant Infectious Disease</i> , 2020, 22, e13222.	1.7	4
10	Pituitary Apoplexy During Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e691-e693.	0.4	3
11	Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. <i>Blood</i> , 2020, 136, 1903-1906.	1.4	34
12	New-onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide. <i>EJHaem</i> , 2020, 1, 576-580.	1.0	2
13	Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S.. <i>Oncologist</i> , 2020, 25, e1117-e1119.	3.7	5
14	Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. <i>Blood</i> , 2020, 135, 1739-1749.	1.4	176
15	Risk factors associated with early viral reactivation following haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: a pilot study. <i>Annals of Hematology</i> , 2020, 99, 1137-1139.	1.8	2
16	Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1137-1146.	2.4	7
17	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. <i>Blood</i> , 2020, 135, 97-107.	1.4	56
18	Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. <i>British Journal of Haematology</i> , 2020, 190, 555-561.	2.5	36

#	ARTICLE	IF	CITATIONS
19	Individual cell motion in healthy human skin microvasculature by reflectance confocal video microscopy. <i>Microcirculation</i> , 2020, 27, e12621.	1.8	8
20	Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2020, 11, 613954.	4.8	3
21	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
22	Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213). <i>Blood</i> , 2020, 136, 45-46.	1.4	11
23	Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment. <i>Blood</i> , 2020, 136, 1-2.	1.4	8
24	Cytomegalovirus Promotes Aberrant Memory CD4 T Cell Differentiation and Immune Function after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 15-16.	1.4	1
25	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. <i>Journal of Clinical Oncology</i> , 2019, 37, 367-374.	1.6	110
26	New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1225-1231.	2.0	14
27	Registries and artificial intelligence: investing in the future of hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 477-480.	2.4	7
28	Noninvasive Microscopic Imaging Reveals Increased Leukocyte Adhesion and Rolling in Skin of Acute Graft-Versus-Host Disease Patients Compared to Post-Transplant Controls. <i>Blood</i> , 2019, 134, 4533-4533.	1.4	2
29	KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208). <i>Blood</i> , 2019, 134, 872-872.	1.4	7
30	Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease. <i>Blood</i> , 2019, 134, 4516-4516.	1.4	2
31	Interobserver Reproducibility of the Myoton and Durometer Devices to Measure Skin Stiffness and Hardness in Chronic Cutaneous Graft-Versus-Host Disease Patients. <i>Blood</i> , 2019, 134, 4515-4515.	1.4	6
32	Key Histopathology Features of Cutaneous Acute Graft-Versus-Host Disease Can be Detected Noninvasively. <i>Blood</i> , 2019, 134, 3278-3278.	1.4	2
33	Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS). <i>Blood</i> , 2019, 134, 599-599.	1.4	0
34	Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2643-2643.	1.4	0
35	Highlights in Graft-vs-Host Disease From the 60th American Society of Hematology Annual Meeting: Commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17 Suppl 6, 16-18.	0.3	0
36	Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2018, 53, 701-707.	2.4	16

#	ARTICLE	IF	CITATIONS
37	Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 795-799.	2.4	2
38	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 393-399.	2.0	24
39	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 78-85.	2.0	9
40	Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 150-155.	2.0	55
41	Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2285-2292.	2.0	38
42	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2216-2223.	2.0	18
43	A Prospective Trial of Extracorporeal Photopheresis for Chronic Graft-versus-Host Disease Reveals Significant Disease Response and No Association with Frequency of Regulatory T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2373-2380.	2.0	31
44	Defining Incidence and Risk Factors for Catheter-Associated Bloodstream Infections in an Outpatient Adult Hematopoietic Cell Transplantation Program. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2081-2087.	2.0	11
45	Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 1589-1592.	2.4	5
46	KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) – Pharmacodynamics and Updated Results. <i>Blood</i> , 2018, 132, 602-602.	1.4	6
47	Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 601-601.	1.4	13
48	Comparison of <i>BCR</i> / <i>ABL1</i> mRNA levels by quantitative real-time PCR in peripheral blood and bone marrow specimens of patients with chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2243-2246.	1.3	2
49	Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1117-1121.	2.0	32
50	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	1.4	52
51	PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	1.4	214
52	Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1473-1477.	2.0	5
53	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	17.0	20
54	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 971-979.	2.0	16

#	ARTICLE	IF	CITATIONS
55	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	3.5	79
56	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017, 130, 2243-2250.	1.4	352
57	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 211-234.	2.0	328
58	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/II Trial. <i>Blood</i> , 2017, 130, 847-847.	1.4	8
59	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	4.1	45
60	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1801-1807.	2.0	11
61	Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1932-1939.	3.2	67
62	Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016, 101, e204-e208.	3.5	1
63	Cardiovascular Complications of Novel Multiple Myeloma Treatments. <i>Circulation</i> , 2016, 133, 908-912.	1.6	36
64	International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 4-10.	2.0	487
65	Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. <i>BMC Genomics</i> , 2015, 16, 727.	2.8	42
66	Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1687-1691.	2.0	65
67	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 690-695.	3.5	29
68	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 780-792.	2.0	124
69	NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 589-603.	2.0	228
70	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 984-999.	2.0	293
71	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 640-645.	2.0	23
72	In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant. <i>Blood</i> , 2015, 126, 5493-5493.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Tacrolimus Metabolism and Risk of Acute Graft Versus Host Disease. <i>Blood</i> , 2015, 126, 1954-1954.	1.4	1
74	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 1618-1623.	3.5	29
75	Referral to Transplant Center for Hematopoietic Cell Transplantation. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1201-1213.	2.2	7
76	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 337-344.	2.0	76
77	Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1341-1348.	2.0	52
78	Geographic Distance Is Not Associated with Inferior Outcome When Using Long-Term Transplant Clinic Strategy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 53-57.	2.0	18
79	Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. <i>Haematologica</i> , 2014, 99, 1746-1752.	3.5	27
80	A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia. <i>Blood</i> , 2014, 124, 1047-1047.	1.4	5
81	FLT3 Mutation Increases Relapse Risk after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia in First or Second Complete Remission: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2014, 124, 322-322.	1.4	4
82	Incidence and Risk Factors Associated with Clostridium Difficile Infection in Cord Blood Transplant. <i>Blood</i> , 2014, 124, 3868-3868.	1.4	0
83	Extracorporeal Photopheresis versus Anticytokine Therapy as a Second-Line Treatment for Steroid-Refractory Acute GVHD: A Multicenter Comparative Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1129-1133.	2.0	83
84	Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium. <i>Blood</i> , 2013, 122, 4614-4614.	1.4	0
85	BCR Hyper-Responsiveness In B Cells From Patients With Chronic Gvhd Is Blocked With The Syk Inhibitor R406. <i>Blood</i> , 2013, 122, 910-910.	1.4	0
86	Genetic Variation in Donor CTLA-4 Regulatory Region is a Strong Predictor of Outcome after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1069-1075.	2.0	18
87	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 296-307.	1.4	559
88	A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 3668-3668.	1.4	1
89	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. <i>Blood</i> , 2011, 117, 4651-4657.	1.4	319
90	Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium. <i>Blood</i> , 2010, 116, 220-220.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors – An Analysis of the CIBMTR. Blood, 2010, 116, 897-897.	1.4	0
92	Genetic Variation In Recipient BAFF Modulates Phenotype of Chronic GvHD After HCT. Blood, 2010, 116, 215-215.	1.4	0
93	Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium. Blood, 2010, 116, 393-393.	1.4	0
94	SNX 2112, An Oral Hsp-90 Inhibitor Exerts Antiproliferative Effects in Combination with Bortezomib and Rituximab in Rituximab Resistant Non-Hodgkin's Lymphoma.. Blood, 2009, 114, 3733-3733.	1.4	2
95	± Regulatory T Cells (Tregs) at Engraftment Predict Long-Term Graft-Versus-Host Disease (GVHD) Outcomes.. Blood, 2009, 114, 2237-2237.	1.4	0
96	Autologous Stem Cell Transplant in Recurrent Diffuse Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early Lymphocyte Recovery and Transplant Outcome.. Blood, 2009, 114, 3407-3407.	1.4	0
97	Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria. Biology of Blood and Marrow Transplantation, 2007, 13, 1207-1215.	2.0	101
98	Evidence-Based Medicine (EBM) Order Set Improves the Management of Patients with Sickle Cell Disease (SCD) Presenting with Severe Acute Pain Episode to the Emergency Room (ER): A Single Center Experience.. Blood, 2007, 110, 3811-3811.	1.4	0
99	Nucleated Cell (NC) Dose of Autologous (Auto) Marrow Graft Is Not Predictive of Engraftment after Auto-Bone Marrow Transplant (auto-BMT) Following Failed Peripheral Blood Stem Cell (PBSC) Mobilization.. Blood, 2006, 108, 5454-5454.	1.4	0
100	Histology Impacts the Outcome of Peripheral T-Cell Lymphomas after High Dose Chemotherapy and Stem Cell Transplant. Leukemia and Lymphoma, 2004, 45, 2261-2267.	1.3	71